Antiplatelet Use Prior to Anticoagulant Initiation in Patients With Atrial Fibrillation-Related Ischemic Stroke: An ELAN Trial Analysis
- Author:
Alexandros A. POLYMERIS
1
;
Masatoshi KOGA
;
Daniel STRBIAN
;
Adhiyaman VEDAMURTHY
;
Manju KRISHNAN
;
Mattia BRANCA
;
Thomas HORVATH
;
Martina GOELDLIN
;
Gek SHIM
;
Christoph GUMBINGER
;
Liqun ZHANG
;
Espen Saxhaug KRISTOFFERSEN
;
Philippe DESFONTAINES
;
Peter VANACKER
;
Angelika ALONSO
;
Sven POLI
;
Ana Paiva NUNES
;
Nicoletta G. CARACCIOLO
;
Markus KNEIHSL
;
Timo KAHLES
;
Daria GIUDICI
;
Silja RÄTY
;
Marjaana TIAINEN
;
Jesse DAWSON
;
Urs FISCHER
;
Author Information
- Publication Type:Original Article
- From:Journal of Stroke 2025;27(2):217-227
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:and Purpose Antiplatelets are often used before direct oral anticoagulant (DOACs) initiation after an acute ischemic stroke related to atrial fibrillation (AF), but the evidence is weak. Here, we explored the risks and benefits of this approach.
Methods:A post-hoc analysis of ELAN (Early versus Late Initiation of Direct Oral Anticoagulants in Post-ischemic Stroke Patients with Atrial Fibrillation) trial data (NCT03148457) was conducted to compare the risk of recurrent ischemic stroke, systemic embolism, major bleeding (extracranial or intracranial hemorrhage [ICH]), and vascular death within 30 days (as a composite and as individual outcomes) in participants treated with and without antiplatelets before DOAC initiation after an AF-associated ischemic stroke. We used both logistic and cause-specific Cox proportional hazards regression in inverse probability of treatment weighted models to account for confounding. We calculated the net benefit of antiplatelet use by subtracting the weighted rate of excess bleeding events attributable to antiplatelets from the rate of excess ischemic events possibly prevented by antiplatelets.
Results:Among 2,013 participants (median age 77 years, 45.5% female), 1,090 (54.1%) used antiplatelets, and 70 (3.5%) experienced the composite outcome. Antiplatelet use was not associated with the composite outcome (inverse probability of treatment weighted odds ratio [ORweighted] 1.06, 95% confidence interval [CI] 0.66–1.72; inverse probability of treatment weighted hazard ratio [HRweighted] 1.06, 95% CI 0.65–1.72), but showed a lower risk of ischemic stroke recurrence (ORweighted 0.58 [0.30–1.08], HRweighted 0.57 [0.30–1.10]), and a higher risk of major bleeding (ORweighted 1.76 [0.56–6.63], HRweighted 1.88 [0.56–6.39]). Its net benefit was +0.57 (95% CI -1.25 to +2.34) to +0.30 (-1.82 to +2.27) weighted events/100 person-months for ICH weights 1.5 to 3.1.
Conclusion:Following an AF-associated ischemic stroke, we found a lower risk of recurrence and no signs of net harm with antiplatelet use before DOAC initiation, despite an increased risk of bleeding.
